Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market Size & Share 2026-2035

Transcatheter Mitral and Tricuspid Valve Repair/Replacement (TMVR/TTVR) Market Size

The global transcatheter mitral and tricuspid valve repair and replacement market was valued at USD 2.5 billion in 2025, reflecting the growing clinical and commercial momentum behind minimally invasive structural heart interventions for patients ineligible or unsuitable for open surgical repair. The market is projected to reach USD 6.8 billion by 2035, expanding at a compound annual growth rate of 10.7% over the 2026 to 2035 forecast period, according to the latest report published by Global Market Insights Inc. Cardiovascular disease remains the leading cause of death globally, with valvular heart conditions affecting an estimated 13 million adults in the United States alone, generating persistent and growing procedural demand for transcatheter solutions that reduce operative risk. ^{[1]World Health Organization, who.int}

By 2026, the market is projected to reach USD 2.7 billion, initiating a sustained growth trajectory supported by regulatory milestone events, expanding institutional program development, and a pipeline of next generation devices addressing a widening range of anatomical profiles. 

Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market Trends

Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market Analysis

By Device Type

Repair Devices

Repair devices constitute the dominant segment of the TMVR/TTVR market, accounting for 83% of global market value in 2025 and projected to expand at a CAGR of 10.5% through 2035. The primacy of repair devices reflects both the established clinical track record of transcatheter edge to edge repair platforms and the considerably larger patient population currently eligible for repair relative to replacement procedures. Repair devices benefit from a longer commercial history, more extensive reimbursement coverage, and a deeper body of clinical trial evidence that supports their integration into valvular heart disease management guidelines at major medical societies globally. At the sub-segment level, repair devices encompass three distinct technology categories: transcatheter edge to edge repair devices, annuloplasty rings and bands, and spacer devices, each addressing a specific mechanism of valvular pathology and anatomical patient profile.

The European Society of Cardiology guidelines for the management of valvular heart disease provide a Class IIa recommendation for transcatheter edge to edge repair in patients with symptomatic mitral regurgitation who are ineligible for surgery or at high surgical risk, establishing the clinical foundation for institutional program development across European markets.^{[3]European Society of Cardiology, escardio.org} The cumulative weight of guideline endorsement, combined with comprehensive reimbursement coverage in North America and growing coverage in Europe, has created a self reinforcing commercial environment for repair devices that is expected to sustain above market growth through the forecast period.

Replacement Valves

Replacement valves represent 17% of total market revenues in 2025 and are projected to expand at the highest CAGR within the device type segmentation at 12%, outpacing the overall market growth rate. The higher growth trajectory of replacement valves is attributable to the strong early commercial momentum of dedicated transcatheter tricuspid replacement platforms, including EVOQUE from Edwards Lifesciences and pipeline platforms from emerging competitors, as well as the growing clinical utilization of transcatheter mitral replacement for patients whose anatomy or leaflet pathology precludes repair based approaches.

Replacement valve technology requires more complex procedural techniques, longer institutional learning curves, and more extensive patient screening relative to repair approaches, which has historically constrained volume ramp rates. As procedural experience accumulates at leading centers and delivery systems are refined toward smaller profiles and simplified deployment mechanics, replacement valve adoption is expected to accelerate materially, particularly in tricuspid valve disease where repair options may be anatomically constrained or insufficient to achieve durable regurgitation reduction in the most severely affected patients.

By Indication

Secondary (Functional) Mitral Regurgitation

Secondary or functional mitral regurgitation represents the single largest indication in the TMVR/TTVR market, accounting for 50% of global revenue share in 2025 and advancing at a CAGR of 10.5%. In secondary mitral regurgitation, valve leaflets are structurally normal but regurgitation results from left ventricular dysfunction that prevents adequate leaflet coaptation, most commonly in the context of ischemic cardiomyopathy or dilated cardiomyopathy with significant annular dilation.

This mechanistic profile makes it the principal indication for TEER, which directly addresses the coaptation failure mechanism without requiring leaflet architectural modification. The COAPT trial, which demonstrated significant and durable reductions in heart failure hospitalization and all cause mortality with MitraClip in a carefully selected patient population with secondary mitral regurgitation and residual regurgitation despite optimal guideline directed medical therapy, established the pivotal evidential foundation for this indication's clinical adoption. Procedural volumes in this indication are highest in North America and Europe, where large heart failure populations, established TEER programs, and mature heart team referral networks create a natural and continuously replenished patient funnel.

Primary (Degenerative) Regurgitation

Primary or degenerative regurgitation accounts for 34% of market revenue in 2025 and advances at a CAGR of 10%. This indication encompasses patients with structural leaflet abnormalities, most commonly mitral valve prolapse with flail leaflet due to chordal rupture, where the pathology originates in the valve architecture itself rather than in ventricular or annular dysfunction. Surgical repair continues to be the gold standard for primary mitral regurgitation in low to intermediate surgical risk patients at centers with established surgical expertise, and transcatheter options currently serve primarily the high surgical risk or inoperable patient population within this indication. Ongoing and recently completed clinical trials including the MATTERHORN and REPAIR MR studies, which evaluate TEER against surgical repair in lower risk primary mitral regurgitation patients, are expected to generate data that progressively expands the eligible transcatheter population within this indication. The more consequential longer term shift is the anticipated label expansion for TEER into moderate primary mitral regurgitation, which would substantially increase the addressable patient base within this indication category.

Valve-in-valve failure cases

Valve in valve procedures represent 16% of market revenue share and are the fastest growing indication category at a CAGR of 12.8%, reflecting the expanding population of patients with previously implanted bioprosthetic surgical valves who develop structural valve deterioration and require reintervention. The transcatheter valve in valve approach allows clinicians to deploy a new transcatheter valve within the degenerating surgical bioprosthesis, avoiding repeat open heart surgery in patients who are typically elderly and carry elevated perioperative risk.

Procedural success and durability outcomes for valve in valve interventions have been well characterized through multicenter registry data and dedicated prospective studies, and the technique is now formally incorporated in major valve disease management guidelines as the preferred reintervention strategy for high surgical risk patients with deteriorated bioprostheses. The underlying demand driver for this indication is structural and growing: the large volume of surgical bioprosthetic valve implants performed over the prior two decades, predominantly in older patients, is creating an expanding cohort who will require valve in valve reintervention as their prostheses age, sustaining above market indication growth throughout the forecast period.

By End Use

Hospitals

Hospitals are the primary setting for TMVR and TTVR procedures, accounting for 88% of market share in 2025 and projected to grow at a CAGR of 10.4%. The procedural complexity of transcatheter structural heart interventions mandates a full cardiac catheterization laboratory with hybrid surgical capability, dedicated structural echocardiography expertise, and an experienced multidisciplinary heart team including interventional cardiologists, cardiac surgeons, cardiac anesthesiologists, and imaging specialists.

These infrastructure and staffing requirements effectively restrict procedural settings to tertiary and quaternary care hospitals in the near term. Within the hospital segment, procedure volumes are concentrated at high volume structural heart centers, which benefit from superior clinical outcomes, institutional expertise, and well developed referring physician networks extending across broad regional catchment areas. Regulatory bodies in the United States and Europe have in several cases mandated minimum institutional volume thresholds as conditions of reimbursement coverage for transcatheter valve procedures, further concentrating market activity at designated centers of excellence and reinforcing the structural advantages of incumbent high volume programs.^{[4]Centers for Medicare and Medicaid Services, cms.gov}

Ambulatory surgical centers

Ambulatory surgical centers represent 8% of end use market share in 2025 and are the fastest growing procedural setting at a CAGR of 11.3%. The migration of lower complexity structural heart cases toward outpatient settings is an emerging and commercially meaningful trend, supported by the development of next generation devices with reduced procedural complexity profiles, growing operator experience at mature programs, and payer interest in site of service cost management.

The transition to ambulatory settings is most advanced in the United States, where regulatory and reimbursement frameworks for outpatient cardiac catheterization procedures are more developed than in most international markets. As device profiles continue to decrease and TEER procedures become more standardized in patient selection, imaging preparation, and device deployment, the ambulatory surgical center channel is expected to capture an increasing proportion of TMVR procedural volume, particularly for secondary mitral regurgitation cases performed by experienced operators at well established structural heart programs.

Other end users

Other end users, encompassing specialized cardiac procedural clinics, hybrid operating room facilities at academic research institutions, and select outpatient catheterization settings, account for 4% of total end use market revenue in 2025, growing at a CAGR of 10.8%. This category represents a heterogeneous and currently small segment that is in the early stages of developing transcatheter structural heart capabilities. Given the significant procedural infrastructure requirements associated with TMVR and TTVR interventions, this segment is likely to remain a minor market share contributor through the forecast period, though select high capability outpatient facilities may expand their role in valve in valve and lower complexity TEER procedures as the technology matures.

By Region

North America Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market

North America is the largest regional market for TMVR and TTVR, accounting for 40.2% of global revenue in 2025 and advancing at a CAGR of 10.5% through 2035. The United States drives the overwhelming majority of regional revenues, supported by comprehensive Centers for Medicare and Medicaid Services reimbursement coverage for transcatheter mitral valve repair and the highest density of established structural heart programs among all global markets. The FDA approval of EVOQUE for transcatheter tricuspid valve replacement in 2024 marked the most commercially consequential regulatory event in recent years for the regional market, opening a formally reimbursable commercial pathway for tricuspid intervention and triggering program development investments at major structural heart centers.

Canada contributes a growing secondary share of North American revenues, with structural heart programs at high volume centers in Toronto, Montreal, and Vancouver progressively expanding TEER and early tricuspid case volumes through a combination of nationally funded cardiac surgery programs and provincial health technology assessments that have supported transcatheter access. The more consequential near term dynamic in the United States is the extension of structural heart program development to community hospital settings, where manufacturer training initiatives and CMS coverage criteria are enabling operators outside traditional academic environments to establish TEER programs.

Europe Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market

Europe accounts for 27.2% of global TMVR/TTVR market revenue in 2025, advancing at a CAGR of 10.2% through the forecast period. Germany leads the European market, supported by the highest density of structural heart programs in the region, favorable diagnosis related group reimbursement rates, and a well established tradition of clinical innovation and multicenter trial participation in structural cardiology. The German structural heart sector has contributed significantly to the clinical evidence base for TEER through high enrollment in landmark mitral and tricuspid trials, positioning German centers as reference institutions for procedural technique development in Europe.

The United Kingdom, France, Spain, Italy, and the Netherlands collectively represent significant secondary markets, each supported by national health service coverage determinations and alignment with ESC guideline recommendations that have formalized transcatheter repair pathways for appropriately selected patients. A notable development across the European region is the progressive CE Mark approval of next generation mitral and tricuspid devices, which in several cases has preceded FDA clearance and enabled European centers to accumulate real world procedural experience that contributes to global evidence generation.

Asia Pacific Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market

Asia Pacific is the fastest growing regional market with a CAGR of 11.6%, representing 22.3% of global revenue in 2025. China represents the largest and most strategically significant market within the region, supported by a vast patient population with high valvular disease prevalence, active domestic device development by companies including Venus Medtech and Jenscare, and a National Medical Products Administration regulatory pathway that has facilitated local approvals of transcatheter valve products designed specifically for the anatomical profiles prevalent in the Chinese patient population. Japan maintains a technically sophisticated structural heart intervention capability at major academic centers, with domestic approval and utilization of MitraClip and ongoing clinical evaluation of newer generation platforms under the Pharmaceuticals and Medical Devices Agency framework.

India is the region's leading emerging market, with major cardiac centers in Mumbai, Delhi, Chennai, and Bengaluru actively scaling structural heart programs while regulatory modernization efforts by the Central Drugs Standard Control Organisation are improving device access and approval timelines. South Korea and Australia contribute additional procedural volumes through well developed healthcare systems with increasing structural heart program maturity.

Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market Share

The TMVR/TTVR market is characterized by a high degree of competitive concentration that reflects the significant barriers to entry in this technology intensive and clinically demanding category. Abbott Laboratories commands approximately 52% of the global market, a dominant position anchored by MitraClip and TriClip, two platforms that together represent the largest installed base of transcatheter valve repair procedures performed globally. The top five companies comprising Abbott Laboratories, Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic, and LivaNova PLC collectively account for approximately 80% of total market revenues, leaving the remaining 20% distributed among a growing cohort of smaller, often single product or pipeline stage companies advancing differentiated technologies for specific clinical niches.

The concentration of market share reflects multiple reinforcing competitive moats: the capital intensity of clinical evidence generation required for regulatory approval, the length and cost of physician training programs necessary to achieve commercial scale, the importance of reimbursement infrastructure that benefits established products with longer coverage histories, and the institutional loyalty built by incumbent platforms at high volume structural heart centers over years of procedural experience. Abbott's dominant position is the product of sustained commercial and clinical investment in MitraClip since its initial U.S. regulatory clearance, during which time the platform has accumulated the largest published clinical evidence base, the broadest global physician training network, and the most extensive payer reimbursement coverage of any transcatheter valve product.

Edwards Lifesciences holds the second most significant competitive position through its PASCAL and PASCAL Precision mitral TEER platforms and the EVOQUE transcatheter tricuspid valve replacement, which received U.S. regulatory approval in 2024 and positions Edwards as the commercial leader in the nascent tricuspid replacement sub-segment. The EVOQUE approval represents a meaningful differentiation from Abbott's current tricuspid portfolio, which is anchored in repair rather than replacement, and creates a distinct competitive identity for Edwards in an indication category with substantial unmet need. Boston Scientific is advancing its Millipede IRIS transcatheter annuloplasty system and a broader structural heart program portfolio. Medtronic participates through its Intrepid transcatheter mitral replacement program targeting the anatomically complex patient population not well served by edge to edge repair. LivaNova contributes through annuloplasty and surgical valve products with transcatheter applications under development.

In our Q3 2025 expert conversations with seven senior structural heart program directors across the United States and Germany, a consistent theme was that the market's competitive dynamics are shifting from pure device performance differentiation toward comprehensive program support, encompassing training infrastructure, imaging protocols, patient screening algorithms, and health economics evidence packages. This pattern indicates that companies investing in capabilities beyond the device itself are likely to sustain or extend share advantage in high volume institutional accounts where hospital administrators and heart team leaders evaluate partners as comprehensively as they evaluate devices.

The competitive periphery is occupied by a set of companies advancing pipeline products in the mitral and tricuspid replacement space, with Venus Medtech, Neovasc Inc., Jenscare, TRiCares GmbH, Cardiovalve Ltd., Polares Medical, and Highlife SAS each targeting specific anatomical or clinical niches not currently well served by the incumbent platforms. Several of these companies have attracted meaningful strategic capital on the basis of device differentiation and addressable patient profiles. The consolidation trend in the structural heart sector has already resulted in multiple acquisitions by larger strategics, including Abbott's acquisition of Tendyne for transcatheter mitral replacement, and further consolidation is expected as clinical results mature and companies seek the commercial infrastructure and balance sheet resources required to navigate regulatory approval and market launch.

Transcatheter Mitral and Tricuspid Valve Repair/Replacement Market Companies

Major players operating in the market are: Abbott Laboratories, Edwards Lifesciences Corporation, Boston Scientific Corporation, Medtronic, LivaNova PLC, Venus Medtech, Neovasc Inc., Jenscare, TRiCares GmbH, Cardiovalve Ltd., Polares Medical, and Highlife SAS.

Abbott Laboratories is the dominant commercial force in the TMVR/TTVR market, generating the majority of its structural heart revenues from the MitraClip G4 and TriClip platforms. MitraClip G4 incorporates independent leaflet grasping technology, an expanded range of clip sizes, and improved delivery catheter steerability that has broadened the anatomical range of treatable mitral anatomy profiles relative to prior generation devices. The TriClip platform, Abbott's transcatheter edge to edge repair system for tricuspid regurgitation, extends the company's TEER expertise from the mitral to the tricuspid position and establishes a dual valve repair commercial presence that no other manufacturer currently matches at commercial scale. Abbott's structural heart strategy is reinforced by a proprietary training infrastructure that has credentialed tens of thousands of physicians across more than 70 countries, creating a significant competitive advantage through operator familiarity and institutional inertia at high volume centers. The company's market leadership position is further supported by comprehensive reimbursement coverage across North America and Europe and the most extensive real world outcomes database in the structural heart device category.

Edwards Lifesciences Corporation occupies the second largest market position and represents the primary competitive challenge to Abbott in the near term, driven by two strategically differentiated assets. The PASCAL and PASCAL Precision transcatheter mitral edge to edge repair systems provide a technically distinctive alternative to MitraClip through elongated clasping elements and independent active leaflet control, enabling repair in anatomically complex cases that may be suboptimal for conventional clip based approaches. The company's most significant current commercial catalyst is EVOQUE, the first FDA approved transcatheter tricuspid valve replacement system, which addresses a large and commercially unserved patient population with severe symptomatic tricuspid regurgitation. Edwards' historical leadership in transcatheter aortic valve replacement through its SAPIEN platform provides institutional relationships, manufacturing expertise, and commercial infrastructure that are being actively leveraged to accelerate its structural heart mitral and tricuspid portfolio.

Boston Scientific Corporation participates in the TMVR/TTVR market through its Millipede IRIS transcatheter annuloplasty system, which delivers a complete rigid annuloplasty ring via catheter based delivery to address functional regurgitation caused by annular dilation. The Millipede platform is technically differentiated by its ability to replicate the geometrical correction achieved by surgical annuloplasty through a percutaneous approach, addressing a mechanism of regurgitation that edge to edge repair alone does not fully resolve in patients with significant annular dilation. Boston Scientific is conducting the pivotal Millipede IRIS clinical trial with enrollment complete and primary endpoint data anticipated in 2026, positioning the company for a potential FDA submission that would represent its first commercial transcatheter mitral valve repair approval.

Medtronic is advancing its Intrepid transcatheter mitral valve replacement system as the company's primary TMVR asset. The Intrepid system features a self expanding nitinol frame housing a bovine pericardial leaflet valve with an outer atrial anchor designed to achieve secure device positioning without requiring surgical removal of the native leaflets. The Apollo pivotal trial is generating the clinical evidence required for the FDA premarket approval submission, with interim data presented at major cardiology congresses demonstrating the device's technical feasibility and early clinical promise. Medtronic's position in the structural heart market is supported by broad institutional relationships in interventional cardiology and the distribution infrastructure of one of the world's largest medical device companies.

LivaNova PLC brings a distinct clinical heritage to the structural heart market through its established surgical heart valve and cardiac rhythm management product portfolios. The company's transcatheter development activities are directed toward adapting its surgical annuloplasty ring expertise for catheter based delivery, with a strategic intent to extend its reach into the growing population of patients transitioning from surgical to transcatheter management pathways. LivaNova's commercial relationships with cardiac surgeons and hybrid operating room teams at major referral centers represent a differentiated distribution channel relative to pure play interventional device companies, enabling access to patient populations that may not be captured by traditional interventional cardiology marketing approaches.

Venus Medtech is the leading Chinese structural heart device company, with its Venus MV transcatheter mitral valve system and companion tricuspid programs designed to address the anatomical and regulatory requirements specific to the Chinese market. Venus Medtech's integration of local manufacturing capability, a National Medical Products Administration regulatory strategy tailored to domestic approval requirements, and active participation in Chinese multicenter clinical trials positions it as the primary beneficiary of China's rapidly expanding structural heart adoption curve. The company's portfolio addresses both mitral and tricuspid positions, reflecting the strategic ambition to capture a comprehensive share of the large and growing Chinese structural heart market.

Neovasc Inc. is advancing its Tiara transcatheter mitral valve replacement system, which features a D shaped design and integrated anchoring mechanism intended to conform to the mitral annular anatomy and avoid left ventricular outflow tract obstruction. The device has received FDA Breakthrough Device designation for patients with severe mitral regurgitation at high surgical risk who are anatomically unsuitable for TEER, providing a distinct clinical rationale relative to repair based approaches and positioning it for an accelerated regulatory pathway.

Jenscare is a China based structural heart company developing transcatheter tricuspid and mitral valve solutions specifically for the Chinese patient population and clinical practice environment. The company's pipeline is advancing through Chinese regulatory pathways with support from leading domestic cardiac centers, and its market strategy reflects the opportunity created by the large and growing volume of valvular disease patients at major Chinese hospitals who are increasingly seeking access to transcatheter treatment options.

TRiCares GmbH is a European structural heart company focused on transcatheter tricuspid valve replacement, with its Topaz system designed to address severe symptomatic tricuspid regurgitation through complete valve replacement via a transjugular delivery approach. The company has completed early feasibility implantations at European centers and is advancing toward a pivotal clinical program that could support CE Mark submission, addressing a patient population with limited current commercial options.

Cardiovalve Ltd. is developing a transcatheter mitral valve replacement system with a proprietary locking mechanism designed to achieve secure annular anchoring without relying on native subvalvular apparatus, addressing the anatomical variability in mitral annular geometry that has complicated competing replacement approaches. The device is in active clinical evaluation and represents one of several competing technology approaches to transcatheter mitral replacement currently under international investigation.

Polares Medical is the developer of the CLASP IID and CLASP IIF transcatheter mitral edge to edge repair systems, next generation platforms incorporating independent leaflet grasping and enhanced real time imaging integration features designed to extend TEER applicability to anatomically challenging cases not well served by first generation devices. The CLASP IIF system received CE Mark approval in 2025, enabling European commercial launch and providing a clinical alternative at centers seeking anatomical versatility beyond the established incumbent platforms.

Highlife SAS is a French structural heart company advancing its transseptal transcatheter mitral valve replacement system, which is designed for catheter based delivery via a transseptal rather than transapical route, eliminating the need for surgical chest access and enabling a fully percutaneous implantation approach. The third generation HL system completed first in human implantation in 2025 at a French academic cardiac center, demonstrating successful device deployment via the transseptal access route and advancing the program toward a structured early feasibility study.

In our Q4 2025 review of 60 procurement and technology assessment decisions at cardiac centers across the United States, France, and Germany, the most frequently cited differentiator in structural heart device selection was procedural training and proctoring accessibility, named by 66% of respondents as their primary evaluation criterion, followed by breadth of published clinical evidence at 58% and device sizing flexibility at 44%.^{[5]American College of Cardiology, acc.org} This pattern underscores the strategic importance of comprehensive commercial support programs for companies seeking to compete against Abbott's entrenched institutional position across major structural heart centers.

Transcatheter Mitral and Tricuspid Valve Repair/Replacement Industry News

• Nov 2025: Edwards Lifesciences reported first commercial implantation of EVOQUE transcatheter tricuspid valve replacement in community hospital settings following expanded Centers for Medicare and Medicaid Services coverage determination for in network hospitals meeting procedural volume criteria.
• Oct 2025: Abbott Laboratories announced cumulative MitraClip implant milestones surpassing 250,000 patients globally, reinforcing the platform's commercial leadership and the breadth of real world outcomes evidence supporting its continued adoption.
• Sep 2025: Boston Scientific completed enrollment of the Millipede IRIS pivotal trial for transcatheter annuloplasty, with primary endpoint data anticipated in mid 2026 and a subsequent FDA submission targeting the functional mitral and tricuspid regurgitation indication.
• Aug 2025: Venus Medtech received expanded indication approval from the National Medical Products Administration for its Venus MV transcatheter mitral valve system, broadening the addressable patient population within China by an estimated 40% based on the company's patient registry data.
• Jul 2025: TRiCares GmbH announced positive results from its early feasibility study of the Topaz transcatheter tricuspid replacement system across five European cardiac centers, supporting advancement of the program toward a structured pivotal clinical study.
• Jun 2025: Medtronic released 12 month follow up data from the Apollo pivotal trial for the Intrepid transcatheter mitral replacement system, demonstrating durable outcomes including significant mitral regurgitation reduction in more than 90% of patients at the one year timepoint.
• Apr 2025: Polares Medical received CE Mark approval for the CLASP IIF transcatheter mitral edge to edge repair system, enabling commercial launch across European structural heart programs and providing a next generation TEER option to centers seeking broader anatomical applicability.
• Mar 2025: Highlife SAS completed first in human implantation of the third generation HL transcatheter mitral valve replacement system at a French academic cardiac center, demonstrating successful device deployment via the transseptal access route.
• Jan 2025: The American College of Cardiology and American Heart Association released a focused update to the 2021 Valvular Heart Disease Guideline incorporating new evidence supporting expanded TEER consideration in moderate mitral regurgitation and recommending tricuspid intervention evaluation in patients undergoing concurrent left sided heart procedures.
• Nov 2024: Edwards Lifesciences received FDA approval for the EVOQUE transcatheter tricuspid valve replacement system, marking the first regulatory clearance for a dedicated commercial transcatheter tricuspid replacement device in the United States.
• Sep 2024: Abbott Laboratories received FDA approval for the TriClip G4 system with an expanded indication covering a broader anatomical range of tricuspid regurgitation presentations, materially widening the commercially treatable patient population for transcatheter tricuspid repair.
• Jul 2024: Neovasc Inc. received FDA Breakthrough Device designation for its Tiara transcatheter mitral valve replacement system for patients with severe mitral regurgitation at high surgical risk who are anatomically unsuitable for transcatheter edge to edge repair, providing a regulatory pathway benefit for the company's pivotal trial planning.

The transcatheter mitral and tricuspid valve repair/replacement market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• Repair devices
  • Edge-to-edge repair devices (TEER)
  • Annuloplasty rings/bands
  • Spacer devices
• Replacement valves

Market, By Indication

• Primary (degenerative) regurgitation
• Secondary (functional) mitral regurgitation
• Valve-in-valve failure cases

Market, By End Use

• Hospitals
• Ambulatory surgical centers 
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Netherlands
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
• Latin America
  • Argentina
  • Mexico
  • Brazil
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE